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Abstract 
Background: Bloodstream infection with Candida, or candidemia, is the most common 
Candida systemic infection. In this study, we investigated the characteristics of patients 
with candidemia to provide appropriate perspectives on these patients and reduce the 
associated mortality and morbidity. 
Methods: In this cross-sectional study, all patients with at least one positive blood culture 
of Candida spp. were investigated from April 2015 to March 2016 in Imam Khomeini 
Hospital Complex, Tehran, Iran. 
Results: A total of 74 patients (44 men and 30 women), with the mean age of 53.15±17.89 
years, were enrolled in this study. Non-albicans Candida species was responsible for 
candidemia in 67.6% (50.74). The mean therapy intervals were 7 and 5.6±1.5 days in 
patients who died and were discharged, respectively. The differences in frequencies of 
urinary catheter and mechanical ventilation were statistically significant among patients 
who died and survived (P<0.001). Among the discharged patients, antifungal therapy was 
administered to 30.8% (12.39). The mortality rate was 54.3% (19.35) in the medical ward, 
5.7% (2.35) in the surgical ward, and 40% (14.35) in the intensive care unit (P=0.041). The 
treatment was significantly associated with lower mortality than those with no treatment 
(OR=0.150 [0.023-0.996], P=0.05). 
Conclusion: The number of candidemia cases caused by non-albicans Candida species is 
continuously increasing in our center. We demonstrated the epidemiologic characteristics 
of patients with candidemia and the significant effects of timely and appropriate treatment 
on their outcomes. Further studies are needed to illuminate more aspects of this healthcare 
problem. 
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Systemic fungal infections are one of the most common causes of hospital-acquired 
infections, especially in critically ill patients. Meanwhile, Candida comprises a high 
proportion of these infections (1).
 
Candida, as part of normal human mucosal membrane 
flora, can cause systemic infections in certain conditions, such as mucosal membrane 
disruption, immunodeficiency, malignancies, renal failure, uncontrolled diabetes, post-
surgical procedures, low birth weight or prematurity, and long-term antibiotic use (2-5). 
Bloodstream infection with Candida, or candidemia, is the most common Candida 
systemic infection, which causes serious problems and increases costs in healthcare 
systems and hospitals (6-8). The recent incidence of candidemia has dramatically 
increased with the increase in the number of susceptible patients (9). 
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Although most patients with candidemia are from the 
intensive care units (ICUs), this infection can also occur in 
other hospital wards (10) and is known as one of the most 
common causes of mortality and morbidity in healthcare 
centers, with a mortality rate of nearly 71% (10-12). 
Although Candida albicans is the most common cause of 
candidemia worldwide, cases of infection caused by non-
albicans species have been increasing recently. Non-
albicans Candida species were more common in some 
studies (13, 14), which causes a major dilemma in the 
treatment of infected patients. These changes are associated 
with different etiologies. For example, the prophylactic or 
preemptive use of antifungals such as azoles, inhibit the 
susceptible species, but cannot affect the resistant species; 
therefore, its spread cannot be prevented (15, 16). The 
proliferation of resistant species results in the use of other 
antifungal agents, such as echinocandines or amphotericin B 
(17-19). According to the latest version of the Infectious 
Diseases Society of America (IDSA) guideline for 
candidiasis treatment, published in 2016, echinocandines 
(such as caspofungin) were recommended as the first-line 
treatment for candidemia in adults with and without 
neutropenia, and fluconazole was recommended as the 
second line (20). However, currently, some patients do not 
receive appropriate treatment at the right time. Despite the 
knowledge about candidemia, many aspects of this infection 
remain unknown. In fact, physicians face challenges due to 
epidemiological differences associated with Candida species 
and their antifungal resistance patterns (21).  
Knowing the epidemiological characteristics and 
outcome-associated factors of candidemia in every 
healthcare setting will help physicians choose the best 
treatment approach and reduce the morbidity and mortality. 
In this study, we investigated the characteristics of patients 
with candidemia at Imam Khomeini Hospital Complex of 
Tehran to provide the appropriate perspectives on these 
patients and reduce their mortality and morbidity. 
 
 
Methods  
In this cross-sectional study, we evaluated all patients 
with candidemia from April 2015 to March 2016 in Imam 
Khomeini Hospital Complex, a referral tertiary center in 
Tehran, Iran, with several medical, surgical, pediatric, 
oncology, and ICU wards. Every patient with at least one 
positive blood culture of Candida spp. was included in the 
study and in patients with several candidemic episodes, only 
the first episode was included. The data were extracted from 
patient’s records.  
We collected the demographic data, including age and 
sex; immunodeficiency conditions; admission ward; time 
interval between admission and blood sampling; underlying 
diseases; use of indwelling vascular or urinary catheters, 
mechanical ventilation, and/or oral intubation; and 
colonization site for Candida. Previous antibacterial therapy 
was defined as receiving of at least one oral or parenteral 
antibiotic in a month preceding diagnosis of candidemia 
(22). Moreover, information on empiric antifungal therapy 
during the first 48 h after the blood culture, antifungal 
treatment, time interval between the initiation of therapy and 
following blood culture, treatment duration, and outcome 
(mortality vs. discharge) were collected.  
The study was approved by the Ethics Committee of 
Tehran University of Medical Sciences. Data were analyzed 
by the IBM-SPSS Statistics for windows Version 24 (IBM 
Corp., Armonk, NY, USA) using the Chi-squared, Mann-
Whitney U-test, t-test, and logistic regression model. 
 
 
Results  
A total of 74 patients (44 men and 30 women), with the 
mean age of 53.15±17.89 years, were enrolled in this study. 
Among the 74 patients, 63 (85.1%) had at least one 
comorbidity at the time of candidemia diagnosis, 23 (31.1%) 
had cancer, 21 (28.4%) were immunodeficient, 11 (14.9%) 
had diabetes, and 11 (14.9%) with renal failure. A total of 28 
(37.8%) patients had a history of minor or major surgery in 
last month; 41 (55.4%) and 45 (60.8%) had vascular and 
urinary catheters, respectively; and 39 (52.7%) were 
admitted in the medical wards. Seven (9.5%) patients had 
positive urinary culture for Candida spp. and 1 (1.4%) 
patient had oral candidiasis.Source of candidiasis was not 
found in rest of the patients. 
Non-albicans Candida species were responsible for 
candidemia in 67.6% (50/74) of the patients. None of our 
patients received antifungal prophylaxis, but 15 (20.3%) 
received antifungal treatment within 72 h after the blood 
culture. Among the 15 treated patients, 8 (53.3) and 7 (46.7) 
had fluconazole and caspofungin, respectively. The mortality 
rate was 47.3% (35.74). Table 1 presents the patients’ 
characteristics, risk factors, admission wards, treatments, and 
crude mortality rate. 
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Table 1: Comparison of patient’s characteristics, risk factors, admission wards and treatments according to candida species 
 
 C. albicans 
(n=24) 32.4% 
n(%) 
C. non-albicans 
(n=50) 67.6% 
n(%) 
All 
(n=74) 100% 
n(%) 
Male sex, n (%) 14 (58.3) 30 (60) 44 (59.5) 
Mean age (SD) 53.2 (18.8) 53.1 (17.5) 53.1 (17.8) 
Risk Factors 
Vascular Catheter 13 (54.2) 28 (56) 41 (55.4) 
Urinary Catheter 14 (58.3) 31 (62) 45 (60.8) 
Mechanical Ventilation 12 (50) 21 (42) 33 (44.6) 
Surgury Hx 12 (50) 16 (32) 28 (37.8) 
DM 1 (4.2) 10 (20) 11 (14.9) 
Immunodeficiency 6 (25) 15 (30) 21 (28.4) 
Renal failure 4 (16.7) 7 (14) 11 (14.9) 
Hepatic Failure 3 (12.5) 2 (4) 5 (6.8) 
Bedridden 1 (4.2) 3 (6) 4 (5.4) 
CHF/IHD 3 (12.5) 3 (6) 6 (8.1) 
Cancer 9 (37.5) 14 (28) 23 (31.1) 
Neurologic disorder 3 (12.5) 7 (14) 10 (13.5) 
Admission Ward 
Medical 13 (54.2) 26 (52) 39 (52.7) 
Surgical 4 (16.7) 5 (10) 9 (12.2) 
Hematology/Oncology 0 (0) 4 (8) 4 (5.4) 
ICU 7 (29.2) 15 (30) 22 (29.7) 
Empirical Treatment 
Fluconazole 4 (80) 4 (40) 8 (53.3) 
Caspofungin 1 (20) 6 (60) 7 (46.7) 
Mortality 12 (50) 23 (46) 35 (47.3) 
 
The median age of patients was 56 years. Hence, we 
divided the patients into two age groups (<55 and >55 years) 
and analyzed their characteristics accordingly. The frequency 
of urinary catheter use was 47.2% (17.36) and 73.7% (28.38) 
in patients aged <55 and >55 years, respectively (P=0.02). 
Among the patients with cancer, 16.7% (6.36) and 44.7% 
(17.38) were aged <55 and >55 years, respectively 
(P=0.009).  
Table 2 presents the clinical characteristics of patients 
aged <55 and >55 years. 
The mean therapy interval was 7 days in patients who 
died and 5.6±1.5 days in patients who were discharged. The 
differences in the frequencies of urinary catheter and 
mechanical ventilation use were statistically significant 
among patients who died and were discharged (P<0.001). 
Among the patients who died, 11.4% (4.35) were bedridden  
 
(P=0.03). Among the discharged patients, antifungal therapy  
was administered to 30.8% (12.39), and 53.3% (8.12) of 
them were immunodeficient (P=0.016). The mortality rate 
according to the admission record was 54.3% (19.35) in the 
medical ward, 5.7% (2.35) in the surgical ward, and 40% 
(14.35) in the ICU (P=0.041). There was no mortality 
recorded in the hematology/oncology ward. Table 3 
compares the characteristics of patients who died and were 
discharged. 
The logistic regression model analyzes the relationship 
between the use of urinary catheter and mechanical 
ventilation, bedridden condition, admission ward, and 
treatment.  
Only the treatment was significantly associated with 
lower mortality when compared with no treatment 
(OR=0.150 [0.023-0.996], P=0.05). 
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Table 2: Comparison of the characteristics of the dead and discharged patients 
 Dead 
n (%) N=35 
Discharged  
n (%) N=39 
p-value* 
Male sex, n (%) 12 (65.7) 21 (53.8) 0.423 
Mean age ± SD 55.8±20.5 50.7±15.0 0.223 
Mean Therapy Duration ± SD 6.0± 1.0 12.8 ± 6.5 0.102 
Mean Therapy Interval ± SD 7.0 ± 0.0 5.6 ± 1.5 0.008 
Risk Factors 
Vascular Catheter 21 (60) 20 (51.3) 0.451 
Urinary Catheter 29 (82.9) 16 (41) <0.001 
Mechanical Ventilation 24 (72.7) 9 (23.1) <0.001 
Surgury Hx 10 (28.6) 18 (46.2) 0.119 
DM 3 (8.6) 8 (20.5) 0.149 
Immunodeficiency 6 (17.1) 15 (38.5) 0.420 
Renal failure 6 (17.1) 5 (12.8) 0.602 
Hepatic Failure 3 (8.6) 2 (5.1) 0.556 
Bedridden 4 (11.4) 0 (0.0) 0.030 
CHF/IHD 3 (8.6) 3 (7.7) 0.890 
Cancer 10 (28.6) 13 (33.3) 0.659 
Neurologic disorder 5 (14.3) 5 (12.8) 0.854 
Admission Ward 
Medical 19 (54.3) 20 (51.3) 0.041 
Surgical 2 (5.7) 7 (17.9) 
Hematology/Oncology 0 (0.0) 4 (10.3) 
ICU 14 (40) 8 (20.5) 
Candida Species 
C. Albicans 12 (34.3) 12 (30.8) 0.747 
Empirical Treatment 
Yes 3 (8.6) 12 (30.8) 0.018 
Fluconazole 1 (33.7) 7 (58.3) 0.438 
Caspofungin 2 (66.7) 5 (41.7) 
*p<0.5 is statistically significant 
Table 3: Comparison of the clinical characteristics of patients under and over 55 years old 
 Under 55 n (%) N=36 Over 55 n (%) N=38 p-value* 
Male sex, n (%) 19 (25) 25 (65.8) 0.255 
Mean Rank of Therapy Duration (Day) 8.28 7.58 0.766^ 
Mean Therapy Interval ± SD (Day) 5.7±1.4 6.2±1.6 0.535 
Risk Factors 
Vascular Catheter 19 (52.8) 22 (57.9) 0.658 
Urinary Catheter 17 (47.2) 28 (73.7) 0.020 
Mechanical Ventilation 14 (38.9) 19 (50) 0.337 
Surgery History 13 (36.1) 15 (39.5) 0.766 
Diabetes 3 (8.3) 8 (21.1) 0.124 
Immunodeficiency 14 (38.9) 7 (18.4) 0.051 
Renal failure 3 (8.3) 8 (21.1) 0.124 
Hepatic Failure 1 (2.8) 4 (10.5) 0.184 
Bedridden 3 (8.3) 1 (2.6) 0.278 
CHF/IHD 1 (2.8) 5 (13.2) 0.102 
Cancer 6 (16.7) 17 (44.7) 0.009 
Neurologic disorder 3 (8.3) 7 (18.4) 0.205 
Admission Ward 
Medical 23 (63.9) 16 (42.1) 0.051 
Surgical 6 (16.7) 3 (7.9) 
Hematology/Oncology 1 (2.8) 3 (7.9) 
ICU 6 (16.7) 16 (42.1) 
Candida Species 
C. Albicans 12(33.3) 12 (31.6) 0.872 
Empirical Treatment 
Yes 9 (25) 6 (15.8) 0.325 
Fluconazole 4 (11.1) 4 (10.5) 0.437 
Caspofungin 5 (13.9) 2 (5.3) 
Mortality 
Dead 13 (36.1) 22 (57.9) 0.061 
*p<0.5 is statistically significant            ^ Mann-Whitney U-test was applied 
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Discussion  
Although Candida albicans is still known as the 
dominant species responsible for candidemia, non-Albicans 
species have shown an increasing trend recently. Non-
albicans Candida species were responsible for candidemia in 
67.6% of our patients, which has been consistent with the 
findings in recent studies (23, 24).
 
However, some specific 
predisposing factors of each non-albicans Candida species 
infection (e.g., indwelling urinary catheter for Candida 
parapsilosis and malignancy for Candida glabrata or 
Candida krusei) were inconsistent with our results (25-27). 
The confounding effects of our laboratory facilities, lacking 
the ability to distinguish various non-albicans Candida 
species, should also be considered. 
Candidemia is a hospital-acquired infection with high 
mortality rate (28). The mortality rate in our study was 
47.3%, which is similar to that of the previous studies (28). 
The minimal differences in mortality rate worldwide can be 
explained by the differences in treatment strategies or 
medications, antifungal drug resistance, and epidemiologic 
characteristics of the target population.  
The mortality rate in patients with candidemia varies 
among the different wards. Several evidence supports the 
fact that patients admitted in the ICU and medical ward have 
higher mortality rates than those in other wards (28). Marriot 
et al. reported a mortality rate of 56% among ICU patients 
with candidemia (29), which is almost similar with our data 
showing that the highest mortality rate was observed among 
patients in the medical ward (54.3%), followed by the ICU 
(40%), and the lowest mortality rate was observed in patients 
admitted in the hematology/oncology ward. This difference 
may be due to the severity of the underlying disease, 
comorbidities, and poor general condition of patients 
admitted in medical wards and ICUs. However, the severity 
scores of our patients were not calculated. 
Prolonged antibacterial therapy is a risk factor for 
candidemia (2-4), although 68.9% of our patients had a 
history of previous antibacterial therapy, but we could not 
find any significant association between the type of 
candidemia or age group with this risk factor. Older patients 
had higher frequency of urinary catheter use and cancer in 
our study. Urinary catheters are a source of fungal 
colonization and infection (30), and cancers are favorable 
conditions for these infections. Older patients had an 
insignificant but higher mortality rate than the younger 
patients. The outcome of candidemia greatly depends on the 
administration of proper treatment at the right time. In fact, 
lack of proper treatment is known as an important modifiable 
risk factor for mortality in these patients (31). A study on 
753 patients with candidemia in the United States reported a 
significant better outcome in patients who received timely 
appropriate treatments (32). Our findings were consistent 
with the previous studies that observed low mortality among 
patients who received appropriate treatment. The low 
mortality rate among immunodeficient patients in this study 
can be explained by their high antifungal treatment. 
We only treated 20.3% of patients with candidemia, 
which was approximately 50% than those in the previous 
studies (29, 31). This along with the fact that none of our 
patients took prophylaxis for fungal infections indicates that 
fungal infections including candidemia are vastly 
underestimated and disregarded.   
Treatment using echinocandins such as caspofungin or 
micafungin was associated with low mortality in previous 
studies (32, 33). Nevertheless, studies comparing the 
efficacy of ecinocandins and azole are limited (34). One of 
the few articles in this field compared the efficacy of 
anidulafungin and fluconazole on 345 patients with 
candidemia (34). The result showed greater success rate with 
anidulafungin (75.6% successful treatment with 
anidulafungin vs. 60.2% with fluconazole) (34). 
Nonetheless, our study failed to detect any difference in the 
outcome among patients who received different treatment 
medications (fluconazole vs. caspofungin). This is probably 
due to a small population of treated patients (20.3%); 
therefore, further studies with a larger target population 
should be conducted. This study also has several limitations. 
These include lack of control group, which prevented us 
from evaluating the risk factors and attributed mortality rate 
for candidemia; small target population (especially for 
treated patients), which interfered with the statistical 
analysis; non-differentiation of fungal subspecies; and 
inefficient data collecting systems in our center, which 
caused some missing data.  
In summary, non-albicans Candida species seem to be an 
increasing important cause of candidemia. We demonstrated 
the epidemiologic characteristics of patients with candidemia 
and the significant effects of timely appropriate treatment on 
their outcomes. Further studies are needed to illuminate 
more aspects of this healthcare problem and to determine 
effective treatment strategies for better management of 
patients with candidemia.  
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